Therefore, it appears that only a few genetic markers other than the potential presence of an NPM1 variant and the absence of a BCR::ABL1-TKD mutation can distinguish Ph1-positive AMLs from M-BC-CMLs and link them to Ph1-negative AMLs [43]. This evidence concerns the gene NPM1 and breast cancer.